Suppr超能文献

用于治疗粪便失禁的睾酮持续释放微球。

Testosterone Sustained Release Microspheres for the Treatment of Fecal Incontinence.

机构信息

Pharmaceutical Research & Technology Labs, Astellas Pharma Inc., 180 Ozumi, Yaizu, Shizuoka, 425-0072, Japan; School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.

Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Ibaraki, 305-8585, Japan.

出版信息

J Pharm Sci. 2022 Aug;111(8):2322-2329. doi: 10.1016/j.xphs.2022.03.008. Epub 2022 Mar 19.

Abstract

The objective of this study was to develop a testosterone sustained release formulation for the treatment of fecal incontinence. To suppress the initial burst release of testosterone, which can lead to systemic toxicity, we incorporated a washing step using an aminoalkyl methacrylate copolymer E solution or propylene glycol solution into a typical o/w emulsion method to prepare polylactic-co-glycolic acid microspheres. We used this method to develop a polylactic-co-glycolic acid microsphere formulation that shows sustained release of testosterone for up to one month. Not only did this formulation show a sustained release profile after administration into the intersphincteric groove in minipigs, it also increased both the anal pressure and mass of the external anal sphincter, while keeping systemic testosterone exposure low. Thus, this formulation successfully affected both the internal and external anal sphincters with a sufficient safety profile, deeming it a promising candidate treatment strategy for fecal incontinence.

摘要

本研究旨在开发一种用于治疗粪便失禁的睾酮持续释放制剂。为了抑制睾酮的初始突释,这可能导致全身毒性,我们将使用氨基烷基甲基丙烯酸酯共聚物 E 溶液或丙二醇溶液进行洗涤步骤纳入典型的 o/w 乳液方法中,以制备聚乳酸- 共- 聚乙二醇酸微球。我们使用这种方法开发了一种聚乳酸- 共- 聚乙二醇酸微球制剂,可在一个月内持续释放睾酮。这种制剂不仅在小型猪的肛门直肠间隙内给药后显示出持续释放的特征,而且还增加了肛门内括约肌的压力和质量,同时保持了较低的系统睾酮暴露。因此,这种制剂成功地以足够的安全性影响了内外括约肌,是一种有前途的粪便失禁候选治疗策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验